Search Results
Your search for 3 matches 15339 pages
Showing 13251 - 13300Call for Ideas for Ovarian Cancer Translational Research ‘Dream Team’ Grant
The American Association for Cancer Research (AACR) is accepting submissions of ideas for the Stand Up To Cancer–Ovarian Cancer Research Fund–Ovarian Cancer National Alliance–National Ovarian Cancer Coalition (SU2C-OCRF-OCNA-NOCC) Translational Research Dream Team Grant that will offer up to $6...
Guidelines and Care: What Comes Next?
The goal of clinical, translational, and basic research is, in the end, the betterment of life on earth. Advances in basic and clinical science ultimately should lead to information that, in turn, enables clinicians to make better treatment decisions for individual patients in order to improve...
REVEL: Winning a Questionable Race
The investigators and sponsors of the phase III REVEL trial should be congratulated and probably commiserated. In this large study, reported by Garon and colleagues in The Lancet and reviewed in this issue of The ASCO Post, 1,253 patients with advanced non–small cell lung cancer (NSCLC) were...
Significant Improvement in Overall Survival With Second-Line Addition of Ramucirumab to Docetaxel in Stage IV NSCLC
In the phase III REVEL trial reported in Lancet, Edward B. Garon, MD, of the David Geffen School of Medicine at UCLA/Translational Research in Oncology–US Network, Los Angeles, and colleagues found that the addition of the antiangiogenic vascular endothelial growth factor receptor (VEGFR)-2...
Early Study Finds BRCA-Mutated Pancreatic Cancer Responds to PARP Inhibition Trio
Two-thirds of patients with advanced pancreatic adenocarcinoma who harbored BRCA mutations responded to the combination of veliparib, cisplatin, and gemcitabine in a phase IB trial that is paving the way for future studies of novel poly(ADP-ribose) polymerases (PARP) inhibitors in this challenging...
CTNeoBC Analysis: Response to Neoadjuvant Chemotherapy Varies by Breast Tumor Subtype
Women who achieve a pathologic complete response (pCR) to neoadjuvant chemotherapy rarely have local or regional recurrence of breast cancer, but this largely depends on tumor subtype, which remained an independent predictor of locoregional recurrence when pathologic response was taken into account ...
Fertility Preservation Suggested With Triptorelin in Long-Term Study
Young women with early breast cancer may be more likely to resume menses and become pregnant when treated with a luteinizing hormone–releasing hormone (LH-RH) analog (also known as a gonadotropin-releasing hormone [GnRH] analog) along with chemotherapy, according to the final follow-up of...
Testosterone/Anastrozole Implants Relieve Menopausal Symptoms in Breast Cancer Survivors
Subcutaneous implants containing testosterone in combination with a low dose of anastrozole can relieve menopausal symptoms in breast cancer survivors, according to research presented at the 2014 ASCO Breast Cancer Symposium.1 “Menopausal symptoms can be quite severe in breast cancer survivors in...
With Breast-Conserving Surgery, Margin Status Not a Factor in Recurrence
In a chart review of 754 early-stage breast cancer patients undergoing breast-conserving surgery, margin status did not impact risk of locoregional recurrence or breast cancer-specific survival, though it did predict for overall survival, as did numerous other factors. Tumor biology remained the...
How Accurate Is the Pathologic Assessment of the Partial Mastectomy Specimen?
The pathologic evaluation of lumpectomy margins is “fraught with problems and pitfalls,” said Stuart J. Schnitt, MD, Director of Anatomic Pathology at Beth Israel Deaconess Medical Center and Professor of Pathology at Harvard Medical School, Boston, who was part of a multidisciplinary discussion of ...
Pathologic Complete Response: Understanding the Subtleties
In the neoadjuvant treatment of breast cancer, the importance of achieving a pathologic complete response (pCR) varies substantially by breast cancer subtype. Patients are increasingly interested in this outcome, but it means different things to different patients, according to two breast cancer...
Robert S. Miller, MD, FACP, FASCO, Joins ASCO as Medical Director of Society’s Institute for Quality
Robert S. Miller, MD, FACP, FASCO, Assistant Professor of Oncology and Oncology Medical Information Officer at the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, has been named Medical Director of the Institute for Quality (iQ) of the American Society of Clinical Oncology (ASCO). Dr....
Managing Resistance to Targeted Agents: The Future of NSCLC Therapy
The bane of treating non–small cell lung cancer (NSCLC) patients with druggable mutations has been the development of resistance to targeted agents. New compounds are meeting the challenge of treating resistant disease, according to Fadlo R. Khuri, MD, FACP, Professor and Chair of Hematology and...
Exciting Highlights in Several Types of Lymphoma Presented at Best of ASCO
Antibody-drug conjugates are being tested against several types of lymphomas and for some of these agents, “activity is quite impressive,” Andrew M. Evens, DO, MSc, reported at the recent Best of ASCO meeting in Chicago. Dr. Evens, Professor of Medicine, Chief, Division of Hematology/Oncology, and...
Duration of Androgen-Deprivation Therapy for Patients With High-Risk Prostate Cancer
Optimal duration of androgen-deprivation therapy as part of primary therapy for prostate cancer continues to be an important question. Two well-conducted studies reported recently at the 56th Annual Meeting of the American Society for Radiation Oncology (ASTRO) provide data that can help inform...
Hypofractionated Radiation Much Less Toxic Than Conventionally Fractionated Radiation in Early Breast Cancer
Hypofractionated whole-breast irradiation was associated with much less acute toxicity during radiation therapy compared with conventionally fractionated whole-breast irradiation and also led to improved physical well-being and less physician-reported and patient-reported fatigue 6 months later,...
Stereotactic Body Radiation Therapy Benefits Patients With Early-Stage Inoperable or Advanced Oligometastatic Lung Cancer
The door is open for expanded use of stereotactic body radiation therapy (SBRT) in patients with inoperable early-stage lung cancer and for patients with oligometastatic stage IV non-small cell lung cancer (NSCLC), according to results of two studies presented at the 56th Annual Meeting of the...
Tough Questions About Health-Care Reform Put Economist in Hot Seat
Although diverse stakeholders agree that health reform is needed, there is little consensus on the specifics of that reform. Best of ASCO Seattle attendees put a number of pointed questions to health economist Rena Conti, PhD, of the University of Chicago, asking about thorny issues such as cost...
Relevance of the Hippocratic Oath in the 21st Century
On the face of it, the idea that a code of professional conduct dating to the ancient Iron Age could possibly retain any relevance in the current era of “Big Data,” religious and cultural pluralism, trillion-dollar government budgets, and nanotechnology seems preposterous. Yet the well-publicized...
Chest Radiation Improves Survival and Intrathoracic Recurrence Rates in Extended-Stage Small Cell Lung Cancer
Thoracic radiotherapy extended progression-free survival, reduced intrathoracic recurrences, and improved overall survival at 2 years when added to prophylactic cranial irradiation in patients with extended-stage small cell lung cancer in an international randomized controlled trial.1 “Thoracic...
Obinutuzumab Could Have Synergistic Action With New Tyrosine Kinase Inhibitors
Final results from the phase I/II GAUGUIN study showed that obinutuzumab (Gazyva) monotherapy was active in patients with heavily pretreated relapsed or refractory chronic lymphocytic leukemia, European researchers reported in Blood. In phase II, median progression-free survival was 10.7 months and ...
Updated GEM2005 Trial Confirms Benefit of Melphalan/Bortezomib Combination in Elderly Multiple Myeloma Patients
Melphalan in combination with bortezomib (Velcade) should be maintained as one of the standards of care for the treatment of elderly patients with multiple myeloma, concluded Spanish trialists reporting updated results from the GEM2005 study comparing bortezomib/melphalan/prednisone with...
Cervical Cancer Risks After Negative HPV Test Lower at 3 Years Than After Negative Pap Result
Three-year risks for cervical cancer and cervical intraepithelial neoplasia grade 3 or worse (CIN3+) were lower following a negative test for human papillomavirus (HPV) than following a negative Pap test, according to a large study comparing three cervical cancer screening strategies, HPV or Pap...
In Memoriam: Kelly Traw
Regretfully, The ASCO Post has learned that Kelly Traw, 49, passed away on September 2, 2014, at Johns Hopkins Hospital in Baltimore. While her obituary did not mention a cause of death, it said that, “She will be greatly missed by her extended family and by the many friends who supported her...
A History of Medical Oncology
BOOKMARK Title: Therapeutic Revolution: The History of Medical Oncology From Early Days to the Creation of the SubspecialtyAuthor: Pierre R. BandPublisher: Bentham SciencePublication date: 2014Price: $39.00 (eBook); $78.00 (print on demand); 213 pagesAvailable at: eurekaselect.com According to...
Clinical Trials Actively Recruiting Patients With Lung Cancer
The information contained in this Clinical Trials Resource Guide includes actively recruiting clinical studies of people with lung neoplasms, including stage I and II small cell and non–small cell lung cancers. The studies include phase Ib, II, III, observational, and interventional trials...
2014 Oncology Meetings
NOVEMBER Chemotherapy Foundation SymposiumNovember 4 - 8 • New York, New YorkFor more information:www.chemotherapyfoundationsymp-osium.org Diagnostic Error in Medicine 5th International ConferenceNovember 11-14 • Baltimore, MarylandFor more information:www.hopkinscme.edu/CourseDetail.aspx/80028747...
Professional Associations Collaborate to Launch Stereotactic Radiosurgery Patient Registry
The American Association of Neurological Surgeons (AANS) and the American Society for Radiation Oncology (ASTRO) are partnering to launch and support a national registry for stereotactic radiosurgery (SRS) treatments. The partnership was announced recently at the ASTRO Annual Meeting. The SRS...
Adding Cetuximab to Chemoradiation Did Not Benefit Patients With Advanced Head and Neck Cancer: What Were the Reasons?
Two landmark randomized studies demonstrated improved survival of patients with head and neck cancer receiving the epidermal growth factor receptor (EGFR) antibody cetuximab (Erbitux) concurrent with radiotherapy compared with radiotherapy alone,1 and similar improvement in patients with...
No Benefit Seen for Cetuximab Added to Cisplatin and Accelerated Radiotherapy in Advanced Head and Neck Carcinoma
Use of cisplatin or cetuximab (Erbitux) with radiotherapy improves overall survival in stage III or IV head and neck carcinoma, and adding cetuximab to platinum therapy improves overall survival in metastatic disease. In the phase III Radiation Therapy Oncology Group (RTOG) 0522 trial reported in...
Beyond R-CHOP for Lymphoma
The R-CHOP regimen (rituximab [Rituxan] plus cyclophosphamide, doxorubicin, vincristine, and prednisone) was a major advance in treating diffuse large B-cell lymphoma, but experts are seeking to up the ante and identify ways to continue to improve outcomes beyond that achieved with R-CHOP. “We are...
Experts Debate the Need for Upfront vs Late Stem Cell Transplant in Multiple Myeloma
With powerful new drugs capable of achieving sustained and deep remissions in multiple myeloma, the role of upfront stem cell transplantation is being questioned by experts, who debated the pros and cons at the National Comprehensive Cancer Network (NCCN) 9th Annual Congress on Hematologic...
Variety of Adjuvant Strategies Explored in HER2‑Positive and Other Breast Cancer Types
Adjuvant trastuzumab (Herceptin) was shown to be effective in patients with breast cancers ≤ 2 cm, regardless of estrogen receptor status, in a meta-analysis1 of five chemotherapy trials, but a “pressing question” remaining is whether T1a/b, N0 tumors warrant the use of adjuvant trastuzumab, Andrew ...
For Triple-Negative Breast Cancer, Adding Carboplatin to Anthracycline/Taxane Produces Benefit, but How Much?
Combination chemotherapy for triple-negative breast cancer is anthracycline- and taxane-based and has not really changed much in the past 10 years, but “we are starting to see emerging data with selective activity of platinum agents,” Priyanka Sharma, MD, told participants at the Best of ASCO...
Despite Potential to Overwhelm, Surveys Still Essential Research Tool
The age of the Internet and worldwide connectivity has made it easier than ever to send out surveys to a wide audience quickly and easily. This ease of access can make surveys an affordable and readily available research tool for independent investigators, but it can also make surveys an...
Radiotherapy Should Be Added to Hormone Therapy in Node-Positive Prostate Cancer
Node-positive prostate cancer has typically been excluded from clinical trials, leaving oncologists with little evidence to guide management for this group of patients. A study presented at the European Society for Medical Oncology (ESMO) 2014 Congress sheds light on this issue, providing the...
Long-Term Results of COU-AA-302 Confirm Abiraterone Benefit
Final results of the COU-AA-302 trial continue to support the survival benefit of abiraterone acetate (Zytiga) in men with chemotherapy-naive metastatic castration-resistant prostate cancer, often referred to as the “predocetaxel space.” “The study met the overall survival endpoint and all...
FDA Approves Bortezomib Injection for Previously Untreated Patients With Mantle Cell Lymphoma
The U.S. Food and Drug Administration (FDA) has approved bortezomib (Velcade) injection for previously untreated patients with mantle cell lymphoma. This is the first treatment in the United States to be approved for use in previously untreated patients with mantle cell lymphoma. Bortezomib was...
Novel Oral Agent Treats Cachexia in Patients With Non–Small Cell Lung Cancer
For the first time, studies show that a drug is effective in treating several domains of cancer-related cachexia. Oral anamorelin increased lean body mass, achieved weight gain, and improved quality of life in patients with cancer-related cachexia in two pivotal phase III studies presented together ...
Nivolumab Yields ‘Impressive’ Duration of Response as Late-Line Melanoma Treatment
Nivolumab yielded an “impressive” duration of response when used as second- or third-line treatment for patients with advanced melanoma, according to Jeffrey S. Weber, MD, of the Moffitt Cancer Center in Tampa, Florida, who presented preliminary results of a phase III trial at the European Society...
BRAF/MEK Inhibitor Combinations Impressive in Melanoma Trials
For advanced/metastatic melanoma patients with BRAF mutations, two pathway inhibitors are better than one, according to studies presented at the European Society for Medical Oncology (ESMO) 2014 Congress that demonstrated improved progression-free and overall survival for regimens combining a BRAF...
Encouraging Early Signals for Cediranib in Recurrent Cervical Cancer
Cediranib (a potent tyrosine kinase inhibitor of vascular endothelial growth factor receptor (VEGFR)-1, -2, and -3) produced a modest improvement in progression-free survival and a robust improvement in response rates compared with placebo when added to chemotherapy in patients with recurrent...
High-Risk Benign Breast Lesions: Some Patients Can Avoid Surgery
High-risk atypical benign breast lesions are upgraded to cancer in more than 15% of patients, but the routine excision of such lesions is probably unnecessary. At the 2014 Breast Cancer Symposium in San Francisco, researchers presented information that could guide the selection of patients who...
What Is the Real Risk of Breast Cancer Associated With Atypical Hyperplasia?
Women with atypical hyperplasia have an absolute risk of about 1% per year for developing breast cancer—a level of risk that has been underappreciated. Not enough is being done to protect these women, according to Lynn C. Hartmann, MD, Professor of Oncology at the Mayo Clinic in Rochester,...
Novel Agents May Address Endocrine Therapy Resistance
Progress has recently been swift in the development of new drugs to improve the response to hormone therapy in breast cancer, according to Hope S. Rugo, MD, Professor of Medicine and Director of Breast Oncology and Clinical Trials Education at the University of California, San Francisco, Helen...
Partnering With Community Centers to Advance Oncology Care
Last fall, Richard R. Barakat, MD, FACS, the Ronald O. Perelman Chair in Gynecologic Surgery at Memorial Sloan Kettering Cancer Center, was named to the new position of Deputy Physician-in-Chief for the Memorial Sloan Kettering Regional Care Network and Cancer Alliance, a new initiative meant to...
Linking Biology and Therapy in Chronic Lymphocytic Leukemia
Recent discoveries in biology, therapy, and (most importantly) the interplay between these two have led to groundbreaking advances in chronic lymphocytic leukemia (CLL). These advances underline the impact of the “translational” approach to cancer management in general. Standard of Care...
CLEOPATRA: Survival With Dual HER2 Blockade ‘Unprecedented’
In the final overall survival analysis of the phase III CLEOPATRA trial, HER2-positive metastatic breast cancer patients lived 15.7 months longer if they received pertuzumab (Perjeta) in addition to trastuzumab (Herceptin) and docetaxel, investigators reported at the European Society for Medical...
More on Chemotherapy Costs
I took exception to a number of the comments made by Rena Conti, PhD, in The ASCO Post (“Health-Care Reform Is Changing the Oncology Landscape,” October 15, 2014, page 1). I realize that The ASCO Post is not a peer-reviewed and indexed publication, but as an ASCO member, I also recognize that the...
The 2014 Nobel Prize in Physiology or Medicine Awarded to John O’Keefe, PhD, and Jointly to May-Britt Moser, PhD, and Edvard I. Moser, PhD
The 2014 Nobel Prize in Physiology or Medicine has been awarded with one half to John O’Keefe, PhD, of University College London, and the second half jointly awarded to May-Britt Moser, PhD, and Edvard I. Moser, PhD, of the Norwegian University of Science and Technology in Trondheim, for their...
